SETD2-H3K36ME3: an important bridge between the environment and tumors

Epigenetic regulation plays an important role in the occurrence, development and treatment of tumors. The histone methyltransferase SET-domain-containing 2 (SETD2) plays a key role in mammalian epigenetic regulation by catalyzing histone methylation and interacting with RNA polymerase II to mediate transcription elongation and mismatch repair. As an important bridge between the environment and tumors, SETD2-H3K36me3 plays an important role in the occurrence and development of tumors. Many tumors, including renal cancer, gastric cancer, lung cancer, are closely related to SETD2 gene mutations. As a key component of common tumor suppressor mechanisms, SETD2-H3K36me3is an important target for clinical disease diagnosis and treatment. Here, we reviewed the structure and function of the SETD2 and how SETD2-H3K36me3 functions as a bridge between the environment and tumors to provide an in-depth understanding of its role in the occurrence and development of various tumors, which is of great significance for future disease diagnosis and treatment.

[1]  A. Jemal,et al.  Cancer statistics, 2023 , 2023, CA: a cancer journal for clinicians.

[2]  Feng Yue,et al.  Clinical and histopathologic characterization of SETD2-mutated colorectal cancer. , 2022, Human pathology.

[3]  Mingzhu Liu,et al.  Tumor Cell‐Intrinsic SETD2 Deficiency Reprograms Neutrophils to Foster Immune Escape in Pancreatic Tumorigenesis , 2022, Advanced science.

[4]  S. Jarmalaitė,et al.  The Emerging Role of Chromatin Remodeling Complexes in Ovarian Cancer , 2022, International journal of molecular sciences.

[5]  I. Varela,et al.  Role of SWI/SNF chromatin remodeling genes in lung cancer development. , 2022, Biochemical Society transactions.

[6]  S. Armstrong,et al.  SETD2 haploinsufficiency enhances germinal center-associated AICDA somatic hypermutation to drive B cell lymphomagenesis. , 2022, Cancer discovery.

[7]  D. Koundal,et al.  Global Increase in Breast Cancer Incidence: Risk Factors and Preventive Measures , 2022, BioMed research international.

[8]  Yajie Xiao,et al.  Genomic correlates of programmed cell death ligand 1 (PD-L1) expression in Chinese lung adenocarcinoma patients , 2022, Cancer cell international.

[9]  Qing Li,et al.  Methyltransferase SETD2 inhibits tumor growth and metastasis via STAT1–IL‐8 signaling‐mediated epithelial–mesenchymal transition in lung adenocarcinoma , 2022, Cancer science.

[10]  A. Papanicolau‐Sengos,et al.  DNA Methylation Profiling: An Emerging Paradigm for Cancer Diagnosis. , 2021, Annual review of pathology.

[11]  M. Ladanyi,et al.  Brief Report: Molecular characterization of peritoneal mesotheliomas. , 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[12]  R. Gorlick,et al.  Advancing therapy for osteosarcoma , 2021, Nature Reviews Clinical Oncology.

[13]  Bin Zhao,et al.  Pan-cancer analysis of SETD2 mutation and its association with the efficacy of immunotherapy , 2021, npj Precision Oncology.

[14]  Min Liu,et al.  The histone methyltransferase SETD2 modulates oxidative stress to attenuate experimental colitis , 2021, Redox biology.

[15]  Pengcheng Bu,et al.  Non-coding RNA in cancer , 2021, Essays in biochemistry.

[16]  U. Matulonis,et al.  Phase II Study of the WEE1 Inhibitor Adavosertib in Recurrent Uterine Serous Carcinoma , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[18]  Bryan A. Millis,et al.  The Huntingtin-interacting protein SETD2/HYPB is an actin lysine methyltransferase , 2020, Science Advances.

[19]  I. Ahluwalia,et al.  Revisiting the association between worldwide implementation of the MPOWER package and smoking prevalence, 2008–2017 , 2020, Tobacco Control.

[20]  Jian Zhang,et al.  SETD2 Restricts Prostate Cancer Metastasis by Integrating EZH2 and AMPK Signaling Pathways. , 2020, Cancer cell.

[21]  M. Ji,et al.  Histone methyltransferase SETD2: a potential tumor suppressor in solid cancers , 2020, Journal of Cancer.

[22]  Jingting Jiang,et al.  Histone methyltransferase SETD2 inhibits tumor growth via suppressing CXCL1-mediated activation of cell cycle in lung adenocarcinoma , 2020, Aging.

[23]  Zhi-hua Shen,et al.  [Quantitative proteomics and differential signal enrichment in nasopharyngeal carcinoma cells with or without SETD2 gene knockout]. , 2019, Nan fang yi ke da xue xue bao = Journal of Southern Medical University.

[24]  P. Lu,et al.  Loss of Setd2 promotes Kras-induced acinar-to-ductal metaplasia and epithelia–mesenchymal transition during pancreatic carcinogenesis , 2019, Gut.

[25]  T. Voeltzel,et al.  Downregulation of the histone methyltransferase SETD2 promotes imatinib resistance in chronic myeloid leukaemia cells , 2019, Cell proliferation.

[26]  A. Pandiella,et al.  Genetic mutational status of genes regulating epigenetics: Role of the histone methyltransferase KMT2D in triple negative breast tumors , 2019, PloS one.

[27]  Y. Hayashi,et al.  SETD2 mutations confer chemoresistance in acute myeloid leukemia partly through altered cell cycle checkpoints , 2019, Leukemia.

[28]  S. Rudzki,et al.  Environmental risk factors for cancer - review paper. , 2019, Annals of agricultural and environmental medicine : AAEM.

[29]  Ke Chen,et al.  Integrated Analysis of Genetic Abnormalities of the Histone Lysine Methyltransferases in Prostate Cancer , 2019, Medical science monitor : international medical journal of experimental and clinical research.

[30]  Ming Huang,et al.  Integrated Genomic and Proteomic Analyses Reveal Novel Mechanisms of the Methyltransferase SETD2 in Renal Cell Carcinoma Development* , 2018, Molecular & Cellular Proteomics.

[31]  T. Ho,et al.  Loss of SETD2 Induces a Metabolic Switch in Renal Cell Carcinoma Cell Lines toward Enhanced Oxidative Phosphorylation. , 2018, Journal of proteome research.

[32]  G. Giaccone,et al.  Acquired SETD2 mutation and impaired CREB1 activation confer cisplatin resistance in metastatic non-small cell lung cancer , 2018, Oncogene.

[33]  F. Grebien,et al.  SETD2 in MLL-rearranged leukemia – a complex case , 2018, Molecular & cellular oncology.

[34]  Voichita D. Marinescu,et al.  SETD2 Is Recurrently Mutated in Whole-Exome Sequenced Canine Osteosarcoma. , 2018, Cancer research.

[35]  Saijuan Chen,et al.  Setd2 deficiency impairs hematopoietic stem cell self-renewal and causes malignant transformation , 2018, Cell Research.

[36]  Xin Fan,et al.  SETD2 indicates favourable prognosis in gastric cancer and suppresses cancer cell proliferation, migration, and invasion. , 2018, Biochemical and biophysical research communications.

[37]  S. Armstrong,et al.  SETD2 alterations impair DNA damage recognition and lead to resistance to chemotherapy in leukemia. , 2017, Blood.

[38]  M. Esteller,et al.  Lung cancer epigenetics: From knowledge to applications. , 2017, Seminars in cancer biology.

[39]  J. Qin,et al.  Histone methyltransferase SETD2 modulates alternative splicing to inhibit intestinal tumorigenesis. , 2017, The Journal of clinical investigation.

[40]  Daniel Baumhoer,et al.  Recurrent mutation of IGF signalling genes and distinct patterns of genomic rearrangement in osteosarcoma , 2017, Nature Communications.

[41]  G. O'Neill,et al.  Cyclin-dependent kinase 7 is a therapeutic target in high-grade glioma , 2017, Oncogenesis.

[42]  D. Feldser,et al.  Systematic In Vivo Inactivation of Chromatin-Regulating Enzymes Identifies Setd2 as a Potent Tumor Suppressor in Lung Adenocarcinoma. , 2017, Cancer research.

[43]  Jiejie Xu,et al.  Prognostic Value of SETD2 Expression in Patients with Metastatic Renal Cell Carcinoma Treated with Tyrosine Kinase Inhibitors. , 2016, The Journal of urology.

[44]  P. Gaulard,et al.  Type II enteropathy-associated T-cell lymphoma features a unique genomic profile with highly recurrent SETD2 alterations , 2016, Nature Communications.

[45]  T. Cierpicki,et al.  H3K36 methyltransferases as cancer drug targets: rationale and perspectives for inhibitor development. , 2016, Future medicinal chemistry.

[46]  T. Ho,et al.  Dual Chromatin and Cytoskeletal Remodeling by SETD2 , 2016, Cell.

[47]  M. Ladanyi,et al.  Genomic aberrations frequently alter chromatin regulatory genes in chordoma , 2016, Genes, chromosomes & cancer.

[48]  Nicola D. Roberts,et al.  Genomic Classification and Prognosis in Acute Myeloid Leukemia. , 2016, The New England journal of medicine.

[49]  Gerben Duns,et al.  SETD2: an epigenetic modifier with tumor suppressor functionality , 2016, Oncotarget.

[50]  James E Audia,et al.  Histone Modifications and Cancer. , 2016, Cold Spring Harbor perspectives in biology.

[51]  Jeffrey S. Morris,et al.  The Consensus Molecular Subtypes of Colorectal Cancer , 2015, Nature Medicine.

[52]  Swe Swe Myint,et al.  SETD2 histone modifier loss in aggressive GI stromal tumours , 2015, Gut.

[53]  A. Lopez‐Beltran,et al.  BAP1, PBRM1 and SETD2 in clear-cell renal cell carcinoma: molecular diagnostics and possible targets for personalized therapies , 2015, Expert review of molecular diagnostics.

[54]  Karl J. Dykema,et al.  High-resolution profiling of histone h3 lysine 36 trimethylation in metastatic renal cell carcinoma , 2015, Oncogene.

[55]  K. Shaw,et al.  Gene mutations in primary tumors and corresponding patient-derived xenografts derived from non-small cell lung cancer. , 2015, Cancer letters.

[56]  Y. Chung,et al.  Frameshift mutation of a histone methylation-related gene SETD1B and its regional heterogeneity in gastric and colorectal cancers with high microsatellite instability. , 2014, Human pathology.

[57]  Heather L. Mulder,et al.  The landscape of somatic mutations in epigenetic regulators across 1,000 paediatric cancer genomes , 2014, Nature Communications.

[58]  S. Armstrong,et al.  Mutations in epigenetic regulators including SETD2 are gained during relapse in pediatric acute lymphoblastic leukemia , 2014, Nature Communications.

[59]  D. Haussler,et al.  The Somatic Genomic Landscape of Glioblastoma , 2013, Cell.

[60]  The Cancer Genome Atlas Research Network COMPREHENSIVE MOLECULAR CHARACTERIZATION OF CLEAR CELL RENAL CELL CARCINOMA , 2013, Nature.

[61]  Sivan Sabato,et al.  DNA methylation of distal regulatory sites characterizes dysregulation of cancer genes , 2013, Genome Biology.

[62]  David T. W. Jones,et al.  Mutations in SETD2 and genes affecting histone H3K36 methylation target hemispheric high-grade gliomas , 2013, Acta Neuropathologica.

[63]  Robert A. Martienssen,et al.  RNA interference in the nucleus: roles for small RNAs in transcription, epigenetics and beyond , 2013, Nature Reviews Genetics.

[64]  Peter A. Jones,et al.  A decade of exploring the cancer epigenome — biological and translational implications , 2011, Nature Reviews Cancer.

[65]  P. A. Futreal,et al.  Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma , 2010, Nature.

[66]  T. Roberts,et al.  The mRNA expression of SETD2 in human breast cancer: correlation with clinico-pathological parameters , 2009, BMC Cancer.

[67]  F. He,et al.  Histone methyltransferase protein SETD2 interacts with p53 and selectively regulates its downstream genes. , 2008, Cellular signalling.

[68]  D. Bettcher,et al.  Clinical cancer control and prevention. Eliminating tobacco-induced cancers: a worldwide challenge. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[69]  J. Licht,et al.  Epigenetic regulation of normal and malignant hematopoiesis , 2007, Oncogene.

[70]  C. Allis,et al.  Chromatin remodeling and cancer, Part II: ATP-dependent chromatin remodeling. , 2007, Trends in molecular medicine.

[71]  H. Erdjument-Bromage,et al.  Histone demethylation by a family of JmjC domain-containing proteins , 2006, Nature.

[72]  Fredrik Nyberg,et al.  Contribution of environmental factors to cancer risk. , 2003, British medical bulletin.

[73]  G. Prendergast,et al.  Methylation-sensitive sequence-specific DNA binding by the c-Myc basic region. , 1991, Science.

[74]  M. Ehrlich,et al.  The 5-methylcytosine content of DNA from human tumors. , 1983, Nucleic acids research.

[75]  I. Wistuba,et al.  Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[76]  Zhu Chen,et al.  Erratum to H3K36 histone methyltransferase Setd2 is required for murine embryonic stem cell differentiation toward endoderm [Cell Reports 8, (2014) 1989-2002] , 2014 .

[77]  M. Goodell,et al.  Hematopoietic stem cell development: an epigenetic journey. , 2014, Current topics in developmental biology.

[78]  C. Roberts,et al.  ARID1A mutations in cancer: another epigenetic tumor suppressor? , 2013, Cancer discovery.

[79]  K. Klauke Epigenetic regulation of normal and malignant hematopoiesis , 2013 .

[80]  H. Seitz,et al.  ALCOHOL AND CANCER , 2007 .